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Abstract 
Background: Despite existing evidence regarding the role of testosterone as a pro- tective factor for the kidney 
function in male adults, there are conflicting and in- conclusive results on the influence of testosterone deficiency 
on developing chronic kidney disease (CKD). 
Objective: This study aimed to investigate the incidence and hazard ratio of CKD among male adults with low 
testosterone levels compared to controls with normal testosterone levels. 
Materials and Methods: During a 15-year follow-up study, a total of 1277 eligible male adults aged 20-80 year 
consisting of 605 males with low testosterone levels (< 350 ng/dL) and 672 controls with normal levels 
participating in the Tehran Lipid and Glucose Study were recruited. Cox's proportional hazards models were 
applied to estimate hazard ratios of CKD between the groups after adjusting for confounders. Results: The total 
cumulative incidence rate of CKD at the median follow-up time of approximately 11.2 years was 21/1000 (95% 
CI: 18/1000, 25/1000) and 18/1000 (95% CI: 16/1000, 22/1000) in the low and normal testosterone groups, 
respectively (P = .2). The multivariate Cox model adjusted for age, body mass index, dyslipidemia, hypertension, 
diabetes, and smoking showed that HR of developing CKD in the male adults with low testosterone levels was 
significantly higher than those with normal levels (HR = 1.38; 95% CI: 1.05, 1.80). 
Discussion and conclusion: This study shows a higher hazard ratio of CKD progres- sion in male adults with 
hypogonadism compared to those with normal levels in their later life. Therefore, timely diagnosis and treatment 
of kidney diseases in hypogo- nadal men can prevent the morbidity and mortality from CKD. 
 






Chronic kidney disease (CKD), a serious public health disorder, is characterized by the progressive impairment 
of glomerular function,1 which affects over 10% of the general population.2 This systemic disorder is often 
associated with an increased risk of cardiovascular events and hospitalization.3,4 
Although the pathophysiology of CKD is yet unknown, some major risk factors of this disease are diabetes 
mellitus (T2DM), obesity, hypertension, older age, and smoking.5 In addition,  previ-  ous study has been 
suggested that a disturbance in the sex steroid hormone secretion, in particular, testosterone insufficiency, has an 
important role in  the  progression  of  CKD  in  male  adults.6,7  There  is evidence demonstrating that impaired 
gonadal function (hypogo- nadism) and sexual dysfunction are common findings in uremic men and those with 
CKD.8 Indeed, the influence of sex steroid hormones on the progression of CKD is complicated by inverse 
causation. Accordingly, men with CKD experience disturbances in their sex steroid hormone concentrations.7 
Earlier researches demonstrated that disturbances in the hypothalamus-pituitary-gonadal axis are preva- lent in 
men with CKD.5,9 A large case-control study on over 10,000 men with  prostate  cancer  showed  that  androgen  
suppression  therapy increased the risk of acute kidney injury.10 Another study conducted by Shoskes et al 11 
revealed that low testosterone concen- trations were associated with the increased risk of graft loss in male kidney 
transplant recipients.11 The mechanism responsible for the protection of kidneys by testosterone is not completely 
understood, but it can be attributed to the induction of vasodilation in renal vessels, enhancement of the production 
of nitric oxide, attenuation of inflammation, and reduction of ischemia mediators, that is, vascular endothelial 
growth  factor  (VEGF).12,13  Some  studies  have  revealed a strong reverse relationship between the testosterone  
level  and  the surrogates  of  inflammation  in  different  CKD populations.6,14 
Testosterone deficiency has been suggested  as  a  novel  risk  factor  to induce uremic condition in men.6 Previous 
studies reported that approximately 50%-70% of men with severe CKD have hypogonadism based on the low 
levels of total and free testosterone.15,16 A re- cent study suggested that the early diagnosis of both hypogonadism 
and related comorbidities may be helpful for the patients in terms of changing lifestyle and appropriate 
treatment.17 
Despite existing strong evidence demonstrating the role of testosterone as a protective hormone on the kidney 
function in men, there are controversies on the influence of decreased levels of endogenous testosterone on 
developing CKD in men.4,7,18 This long  term follow-up study aimed to investigate the incidence and hazard ratio 
of CKD among male adults with low concentrations of testosterone compared to controls with normal 
concentrations. 
MATERIAL S  AND METHODS  
Ethics considerations 
This study  was  approved  by  the  Medical   Ethics   Committee   of  the Research  Institute  for  Endocrine  
Sciences  (Code:  IR.SBMU. ENDOCRINE.REC.1398.028). All subjects signed a written informed consent. 
Subjects 
In this ongoing population-based prospective cohort  with  15  years of follow-up, study population were recruited 
from the Tehran Lipid and Glucose Study (TLGS), which was initiated since 1998 to assess the prevalence and 
risk factors of non-communicable diseases. In the TLGS, a total of 15 005 subjects aged ≥3 years were followed 
within a three-year interval to obtain data on demographic, anthropometric, reproductive, hormonal, and metabolic 
characteristics, general physical examinations, and laboratory measurements. Details of the TLGS have been 
reported previously.19 All subjects were visited at the outpatient endocrinology clinic of the TLGS between 
February 1999 and August 2001. The TLGS has five phases, including phase 1(baseline): 1999-2001; phase 2: 
2002-2005; phase 3: 2005-2008; phase 4: 2008-2011; and phase 5: 2011-2014. 
Figure 1 shows the study flow diagram. All male adults aged 20-80 years were assessed using eligibility criteria 
(n = 1462), and 678 male adults had low testosterone levels and 784 had normal testosterone levels. All subjects 
who were visited at the baseline of the study and completed at least one follow-up visit were included. None of 
the subjects had taken supplemental testosterone. The sub- jects with CKD at baseline (n = 158) and lost to follow-




At baseline and follow-up visits, the subjects were evaluated for clini-cal, and anthropometric, and biochemical 
parameters by a well-trained interviewer. Bodyweight was assessed with at the least clothes by a digital scale (Seca® 
707, Seca GmbH) and rounded to the nearest 100 grams. In the same way, height was assessed without shoes in the 
standing position and normal posture of shoulders by a tape measure. We calculated body mass index (BMI) based 
on the following formula: weight in kilograms (kg) divided by height squared (m2). Waist circumference was assessed 
with an unstretched tape measure at the level of the umbilicus, without any pressure to the body surface. Hip 
circumference was assessed at the level of the anterior-superior iliac spine without any pressure to the body 
surface. We also assessed the sys tolic and diastolic blood pressure twice on the right arm in the seated posture using 
a standard mercury sphygmomanometer after 15 mines of rest; then, the mean of these measurements was recorded. 
For this study, serum samples were taken after 12 h of overnight fasting between 7:00 and 9:00 AM; all analyses 
were conducted at the TLGS laboratory on the same time of blood collection. We stored all sera at −80°C until 
use (testing). We measured fasting blood sugar (FBS) by an enzymatic colorimetric method using the glucose 
oxidase. Serum triglyceride (TG) concentrations were measured using glycerol phosphate. Total cholesterol (TC) 
was assayed using the enzymatic colorimetric method using cholesterol esterase and cholesterol oxidase. The level 
of high-density lipoprotein cho- lesterol (HDL-C) was assayed after precipitation of the apolipoprotein B (apo 
B)–containing lipoproteins using phosphotungstic acid. We used a modified Friedewald to estimate LDL-C. All 
metabolic parameters were assessed using related kits (Pars Azmon® Inc, Tehran, Iran) and a Selectra 2 autoanalyzer 
(Vital Scientific®, Spankeren, the Netherlands). The intra- and inter-assay coefficients of variations (CVs) were 
both 2.2% for glucose. For total and HDL cholesterol, intra- and inter-assay CVs were 0.5 and 2%, respectively. 
Intra- and inter-assay CVs were 0.6 and 1.6% for TG, respectively. 
We assayed testosterone and SHBG levels using enzyme immunoassay (DRG, diagnostic®, GmbH, Germany) 
by the sunrise ELISA reader (Tecan Co®, Salzburg, Austria); the intra- and inter-assay CVs were 5.7, 8.4, and 
9.6, 8.6% with the detection limit of 0.022 ng/ ml and 0.1 ng/ml, respectively. We also calculated free 
testosterone index (FTI) based on the following formula: testosterone (nmol/L)/ SHBG (nmol/L) × 100. 
Finally, we measured levels of serum creatinine (Cr) using the kinetic colorimetric Jaffe. The sensitivity of 
the assay was 0.2 mg/dl (range, 18-1330 µmol/L (0.2-15 mg/dl)). Reference intervals based on the 
manufacturer's recommendation were 53-97 µmol/L (0.6-1.1 mg/dL) in male adults. Intra-assay and in- ter-
assay CVs were less than 3.1% in both baseline and follow-up visits. We carried out all biochemical assays 
through commercial kits (Pars Azmoon Inc ®, Tehran, Iran) by a Selectra 2 autoanalyzer (Vital Scientific®, 
Spankeren, the Netherlands). Assay perfor- mance was monitored after every 25 tests by lyophilized serum 
controls in normal and pathologic ranges, and all samples were analyzed when internal quality control met the 
standard accept- able criteria.20,21 
Definitions 
According to the recommendations of the International Society for the Study of the Aging Male (ISSAM)22 and 
the International Society for Sexual Medicine (ISSM),23 low testosterone was determined as concentrations of 
total testosterone <350 ng/dL, otherwise as to the normal total testosterone. 
Based on the Kidney Disease Outcome Quality Initiative (K/ DOQI) guidelines, CKD was defined as either 
kidney damage or glomerular filtration rate (GFR) <60 mL/min/1.73 m2 for >3 months.24 We estimated GFR 
based on the abbreviated prediction equation provided by the Modification of Diet in Renal Disease (MDRD) 
study as follows: 
  
GFR = 186 × SCr −1.154 × Age −0.203 
 
In this equation, eGFR (estimated GFR) and serum creatinine (Scr) levels are expressed as mL/min per 1.73 m2 
and mg/dL. According to guidelines, CKD was considered an eGFR below than 60 mL/ min/1.73 m2 
happening at any time during the follow-ups.25 
We also classified men  based  on  their  GFR;  those  with GFR ≥ 90 ml/min/1.73 m2 were defined as normal 
or high GFR, 60-89 as mildly decreased, 45-59 as mildly to moderately decreased, 30-44 as moderately to severely 
decreased, 15-29 severely decreased, and <15 as kidney failure.26 
Hypertension was diagnosed based on the JNC-VI criteria 27 in- cluding a mean SBP ≥ 140 mm Hg, mean DBP 
≥ 90 mm Hg, or the current use of anti-hypertensive medicine.28,29 
We considered type 2 diabetes mellitus as fasting blood sugar (FBS) ≥7 mmol/L (measured twice), 2-h post-
challenge plasma glucose (PCPG) ≥11.1 mmol/L, or taking anti-diabetic drugs.30 
Men participating in the study were classified based on the smoking status; smokers were defined as those who 




We investigated continuous variables for normality based on the one-sample Kolmogorov-Smirnov test; 
they presented as mean ± standard deviation if they had a normal distribution, or median with inter-quartile range 
(IQ25-75) for variables with skewed distribution. Categorical variables were presented as percentages. All 
comparisons between the low and normal total testosterone concentration groups were carried out using Student's 
unpaired t test, Mann-Whitney U test, and chi-square test. Exact test method for two-way contingency table was 
used to get p-values comparing severity of CKD in testosterone categories (low vs. normal). We used the 
following formula to estimate the person-time incidence rate of CKD: the number of new events in the study 
time divided by the sum of person-time (person * year) at risk. The Kaplan-Meier plots and log-rank tests were 
used to investigate the relationship of testosterone levels with time to CKD progression. We applied the 
multivariable Cox proportional hazards regression model to estimate the hazard ratio (HR) with a 95% confidence 
interval (CI) between the low and normal testosterone concentration groups, which was adjusted for age, BMI, 
dyslipidemia, hypertension, diabetes, and smoking. We tested the proportionality of the model as a whole and get 
a test of proportionality for each predictor using goodness-of- fit (GOF) tests. The follow-up time was drawn 
from the difference between the calculated mid-time date and the date at which the subjects entered the study. For 
the censored or lost to follow-up subjects, the survival time was the interval between the first and last observation 
dates. 
We assessed the relationship between total testosterone and CKD using three separate models. The first model 
compared low (<350 ng/dL) vs. normal total testosterone levels as a grouping variable. The second survival 
model used continuous log testosterone, and the third model used testosterone quintiles adjusted for potential 
covariates. The testosterone was selected in a binary manner because it was more beneficial to clinicians. 
Statistical analysis was performed using software package STATA (version 14; STATA Inc, College Station, TX, 




During up to 15 years of follow-up, 1277 eligible subjects met inclusion criteria and were recruited (Figure 1). 
The median and inter-quartile ranges for follow-up years of the low and normal testosterone level groups were 
11.0 (10.2-11.9) and 11.4 (10.4-12.4), respectively. At baseline, mean age and BMI were 42.0 ± 12.6 years and 
25.3 ± 3.9 kg/m2. Also, 12.6% and 68.8% of the subjects had a history of hypertension and dyslipidemia, 
respectively. 
At baseline, 74 (5.8%) had a history of diabetes. Of these, 63 (85.1%) had normal testosterone and 11 (14.9%) had 
low testoster- one. At the end of follow-up, the number of diabetic men reached 122 with 88 subjects in normal 
testosterone and 34 subjects in low testosterone group. In addition, of these 122 diabetic patients, 43 men 
developed CKD. Out of these 43 subjects, 36 men were in nor- mal T category and 7 men were in low T category. 
The median and inter-quartile ranges for duration of developing CKD in diabetics were 6.4 (4.1-11.9) years. 
Median (IQR) of total testosterone, SHBG, and FTI was 3.7 (3.0- 5.2), 31.0 (20.4-43.2), and 40.6 (25.9-63.9), 
respectively. In this prospective study whose total testosterone was assayed for clinical indications, 605 of 1277 
(47.4%) men had low total testosterone levels. Table 1 illustrates the comparison of baseline features for male 
adults with low and normal total testosterone levels. There were significant differences in markers of SHBG, LDL, 
FTI, diabetes, and hypertension among men with low versus normal total testosterone levels. 
According to classification system GRF in CKD, 109 men classified as normal and 1168 men as mildly decreased 
GFR category. However, at the end of follow-up with 1048 available data for GFR, there were 48, 794, 194,10, 
and 2 men in categories of normal, mildly decreased, mildly to moderately decreased, moderately to severely 
decreased, and severely decreased, respectively. P-values obtained from exact test method for two-way 
contingency table showed no association between severity of CKD and testosterone levels (Table S1). 
The total cumulative incidence rate of CKD at the median follow-up time of almost 11.2 years was 21/1000 
(95% CI: 18/1000, 25/1000) and 18/1000 (95% CI: 16/1000, 22/1000) in the low and normal testosterone groups, 
respectively (P = .2). 
 
Of 1277 eligible men participating in the study, 293 (22.9%) developed CKD during the median follow-up time. 
The survival curves illustrated the time to the development of CKD for male adults with low vs. normal 
testosterone levels. Based on log-rank P-value, the survival curves for men with low testosterone 
concentrations were significantly different from those of normal levels (P = .045) (Figure 2). 
The multivariate Cox model adjusted for age, body mass index, dyslipidemia, hypertension, diabetes, and 
smoking showed that HR of developing CKD in males with low testosterone levels was significantly higher than 
those with normal levels (HR = 1.38; 95% CI: 1.05, 1.80). We included age in the multivariate Cox model as a 
time-de- pendent variable as the GOF test for the age variable was significant (P-value = 0.01). 
Although in the model adjusted for the previously mentioned variables, the log testosterone concentration was 
not significantly related to CKD [HR = 0.82; 95% CI: 0.61, 1.10]; in the unadjusted model, every unit increase 
in the log testosterone level revealed that the HR of CKD decreased by 25% (HR = 0.75; 95% CI: 0.57, 0.98). 
In the quintile model, the lowest quintile of total testosterone (66-288 ng/dl) was associated with higher HR of 
CKD progression comparison with the highest quintile (550-1500 ng/dl) (HR = 1.58; 95% CI: 1.04, 2.40). When 
using a Bonferroni correction to adjust for 3 ways, testosterone was evaluated (P = .05/3 = 0.017), and the 
comparison between the low (<350 ng/dl) and normal total testosterone analysis (P = .016) was the only result 
suggesting a significant relationship of the testosterone level with CKD (Table 2). 
In addition, we considered interaction term between diabetes and testosterone groups in our Cox model, but 




Findings from earlier investigations suggest a protective effect of testosterone on the kidney function, although 
strong evidence on the relationship between testosterone deficiency and progression of CKD was scarce. This 
long-term population-based follow-up study provides evidence on the incidence and hazard ratio of CKD in male 
adults with testosterone deficiency in comparison with those with normal testosterone levels. 
Over an approximate median follow-up of 11 years, this study demonstrated that the hazard ratio of developing 
CKD in males with low endogenous testosterone concentrations was 1.26-fold (95% CI: 1.02, 1.60) higher than 
those with normal levels. Our findings were significant even after multiple adjustments for potential con- founders 
related to CKD including age, BMI, smoking, dyslipidemia, diabetes, and hypertension (HRadjusted: 1.38; 95% 
CI: 1.05, 1.80). This study found that the hazard ratio of progressing CKD was significantly higher in the lowest 
quintile of testosterone than the highest quintile (the reference range) (HR adjusted = 1.58; 95% CI: 1.04, 2.40). 
The mechanism responsible for the protection of kidneys by testosterone is not completely understood, although 
it can be at- tributed to the induction of vasodilation in renal vessels, enhancing the production of nitric oxide, 
attenuation of inflammation, and the reduction of ischemia mediators, that is, VEGF.12,13 There is a strong 
document demonstrating a strong inverse relationship between the testosterone level and surrogates of 
inflammation in various populations of CKD.6,14 On the other hand, treatment of androgen deprivation can induce 
an increased risk of damage to the glomerulus through antagonizing testosterone. Some animal models have shown 
that testosterone repletion keeps from harm the kidney, whereas castration promotes renal dysfunction and injury 
that is independent of conversion to estradiol. Data from experimental investigations suggest that testosterone may 
protect against ischemia-reperfusion–induced acute kidney injury, possibly through the attenuation of 
inflammation and mediators of ischemia.31 An in vitro research demonstrated that mesangial cells derived from 
male rats produced more fibronectin, TNF-a, and IL-b involved in inflammation and fibrosis, than cells derived 
from female rats.32 In addition, some investigators reported that the exogenous administration of testosterone may 
induce the activation of the renin-angiotensin system (RAS), the production of endothelin, and the regulation of 
anti- or/ and proinflammatory cytokines involved in the pathogenesis of hypertension and kidney damage,33,34 
suggesting a potential contributing androgens in developing kidney impairment and supporting the hypothesis that 
the decrease in renal function in men occurs at a faster rate than in women.9 Further clinical studies confirmed the 
role of inflammatory mechanisms in developing CKD caused by testosterone insufficiency. For example, a cross-
sectional study by Yilmaz et al35 showed that advanced CKD is inversely associated with hypertension, 
endothelial disturbance, and the increased risk of cardiovascular events.35 Another investigation by Carrero et al 
36 on a cohort of 126 men undergoing hemodialysis showed that independent of age, serum creatinine, and sexual 
hormone–binding globulin (SHBG), testosterone levels were inversely and strongly related to the inflammatory 
markers IL-6 and CRP.36 
Despite existing several investigations on testosterone deficiency and kidney diseases, no other prospective study 
is available on the influence of decreased levels of testosterone on progression of CKD in male adults. 
Observations from a cross-sectional study by Yi et al7 in the United States on 1400 adult men were in contrast 
with our results. They showed that the mean free testosterone concentration was higher in men with an eGFR < 
60 mL/min/ 1.73m2 than in men with a higher eGFR.7 As those studies had a cross-section de- sign, reverse 
causation could not be ruled out. Similar to our findings, a recent cross-sectional study by Kurita et al18 
demonstrated that having low free testosterone levels were related to reduced eGFR in adult men after 
adjustment for potential confounders such as sociodemographic characteristics, comorbidities, and blood 
pressure. A prospective follow-up study by Maric et al37 demonstrated that developing diabetic nephropathy in 
male adults with type I diabetes was related to lower endogenous testosterone levels and increased circulating 
estradiol levels. These findings were in line with our findings and highlighted the role of steroid imbalance in the 
progression of kidney diseases. 
Hypogonadism in male adults with CKD may associate with a higher risk of cardiovascular events and mortality, 
particularly in those undergoing hemodialysis.4 Haring et al3 using a prospective population-based study with a 
median follow-up of 9 years found that men with CKD and low total testosterone significantly had higher all-
cause mortality compared to those with normal levels (HR, 1.42,95% CI, 1.09-1.84),3 confirming the effect of 
testosterone deficiency on developing CKD. Also, a recent retrospective study by Khurana et al4 on 2419 men 
with severe CKD showed that a higher total testosterone level was associated with lower mortality when it was 
examined as a continuous variable, but they did not observe any significant difference in the mortality and survival 
of patients when testosterone was classified as a qualitative variable (low vs. normal). However, it should be 
considered that these two cohort studies assessed all-cause mortality and hence could not infer causality. In this 
study, total testosterone was considered a preferred androgenic marker. Although theoretically, bioavailable 
testosterone is the most accurate parameter to identify testosterone deficiency, because a standard method to 
measure this parameter has not been established, total testosterone is the most widely accepted substitute 
parameter.38,39 However, it should be noted that the use of total testosterone level for the diagnosis of 
hypogonadism in elder indi- viduals may result in under-diagnosis because SHBG increases with age and albumin 
decreases.40 
Although testosterone levels in male adults decrease with aging (approximately 0.12 nmol/L per year),41,42 it is 
progressive through- out life and there is no set point in women during menopause. In ad- dition, there is a variation 
in testosterone assays. For such reasons, no precise cutoff value is available for deficient endogenous testos- 
terone in male adults. However, in this study, based on the recom- mendations of the ISSAM22 and the ISSM,23 
a cutoff value < 350 ng/ dl was considered as a low testosterone level. 
To the best of our knowledge, this is the first prospective study with a long-term follow-up duration evaluating 
the influence of testosterone deficiency on the progression of CKD in male adults. The strength of this study is 
its design as a population-based prospective study with over a decade of follow-up and short-term intervals. In 
addition, the acceptable level of lost to follow-up, accurate measurements, and statistical analysis adjusted for 
age, body mass index, dyslipidemia, hypertension, diabetes, and smoking status at baseline could help to reach 
more precise results. 
However, this study has also some limitations, which should be considered to interpret the results. In the current 
study similar to most epidemiologic studies, CKD was defined based on a limited number of creatinine 
measurements and these measurements could not be repeated within 3 months to confirm a chronic reduction in 
GFR. In addition, testosterone levels were measured only once in this study as at baseline, which can result in 
variability in hormone concentrations.22 Finally, although we tried to run different models to control all major 
confounders for which data were available, possibly confounding factors such as physical activity could not be 
assessed because of limitations in data collection. 
CONCLUSION 
 
In this study, a higher hazard ratio of CKD progression was reported in male adults with hypogonadism compared 
to those with normal levels in their later life. In addition, faster development of CKD was observed compared 
with those with normal testosterone levels. Our results suggest that the early diagnosis and managing subsequent 
kidney diseases in hypogonadal men can potentially prevent the morbidity and mortality from CKD. 
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FI G U R E 2 Kaplan-Meier plot indicates survival (time to CKD) curves for normal testosterone (≥350 
















































TA B L E 1 Baseline characteristics of the subjects in the groups 
 






N = 605 
(≥350 ng/dl) 
N = 672 
 
P-valued 
Age (year)a 42.1 ± 12.6 41.8 ± 12.6 .7 
Follow-up time (year)b 11.0 (10.2-11.9) 11.4 (10.4-12.4) <.001 
Body mass index (kg/m2)a 25.3 ± 3.6 25.3 ± 4.2 .9 
Systolic blood pressure 
(mm/Hg)a 
115.2 ± 14 118.6 ± 17.8 <.001 
Diastolic blood pressure 
(mm/Hg)a 
75.4 ± 9.5 77.1 ± 10.8 .002 
Waist Circumference (cm)a 86.9 ± 9.7 86.7 ± 11.4 .7 
Waist-hip ratioa 0.9 ± 0.1 0.9 ± 0.1 .2 
Smoking historyc, n (%) 237 (39.2) 288 (42.9) .1 
Dyslipidemiac, n (%) 412 (68.1) 467 (70.1) .2 
Sex hormone–binding 
globulin (nmol/L)b 
30 (19.1-41.7) 33.7 (22.3-46.2) .002 
Free testosterone indexb 34 (23.6-51.2) 56.3 (39.1-90.4) <.001 
Total cholesterola 203.7 ± 39.7 200 ± 39.8 .1 
High-density lipoprotein 
(mg/dl)a 
39.5 ± 9.4 39.2 ± 9.6 .6 
Low-density lipoprotein 
(mg/dl)a 
132.2 ± 33.6 128 ± 34.7 .03 
Triglyceride (mg/dl)b 140 (102-196.5) 146 (97-207) .5 
aValues are presented as mean ± SD. 
bPresented as median (inter-quartile 
range). cData shown as percentage. 
dSignificant differences (P-value < .05), analyzed using independent t test for 
superscripts a, Mann- 



























TA B L E 2    Cox proportional models of total testosterone vs. CKD 
 
 Unadjusted Adjusted* 
Low (<350 ng/dL) vs. 

















289-336 1.08 (0.74, 
1.58) 
1.20 (0.77, 1.85) 








550-1500 1.00 (reference) 1.00 (reference) 
Note: Association was given as hazard ratio (95% 
confidence interval). 
*Adjusted for age, BMI, smoking history, diabetes, 
dyslipidemia, hypertension. 
 
 
